AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01508741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 5-Aminolevulinic Acid (5-ALA)
Description: 5-ALA 50 mg. p.o. daily capsules taken over 6 weeks.
Study NCT01508741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily p.o. capsule of similar shape and color to active ingredient 5-ALA capsule taken over 6 weeks.
Study NCT01851733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study NCT01851733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw - dendritic cells
Description: The second 10 patients enrolled to Arm B:~* before MLA (up to 3 days before)~* 2 weeks after MLA~* 4 weeks after MLA~* every 2 weeks thereafter for up to 3 months after biopsy (provided there is no significant chemotherapy induced cytopenia)
Study NCT01851733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Susceptibility Contrast Magnetic Resonance Imaging
Study NCT01614730 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Modified Neurotech Vital Device
Description: verify no contraction is stimulated in the Modified Neurotech Vital.
Study NCT01614730 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurotech Vital Device
Description: Checking there is a contraction of the pelvic floor muscle when the treatment is administered with the Neurotech Vital Device
Study NCT01874756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY500307 150mg
Description: LY500307 150mg daily dose (6 capsules of 25mg) for 8 weeks
Study NCT01874756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY500307 75mg
Description: LY500307 75mg daily dose (3 capsules of 25mg and 3 capsules of placebo) for 8 weeks
Study NCT01874756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 placebo capsules daily for 8 weeks
Study NCT01874756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY500307 25mg
Description: LY500307 25mg daily dose (1 capsules of 25mg and 5 capsules of placebo) for 8 weeks
Study NCT01173042 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peanuts
Description: Shake containing 3.0oz of peanuts (including skin) + control (heavy whipping cream, glucose and chocolate syrup)
Study NCT01173042 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Glucose and whipping cream
Description: An oral liquid glucose (75g) and fat (high saturated fat from 60g heavy whipping cream) load. Chocolate syrup is added for flavor.
Study NCT01173042 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oil Blend
Description: Shake containing an oil blend (sunflower, sesame, olive and palm oils) + control (heavy whipping cream, glucose and chocolate syrup). The amount of oil added to the control will provide an equivalent amount of fat to that provided in 3 oz (85g) of peanuts
Study NCT01678638 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IH repair before NICU discharge
Description: The IH repair is performed prior to NICU discharge (within 1-2 weeks of enrollment and randomization)
Study NCT01678638 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IH repair at 55-60 weeks post-menstrual age
Description: The IH repair will be performed as an outpatient between approximately 55-60 weeks post-menstrual age.
Study NCT03535207 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: high dose chemoradiotherapy
Description: Radiation therapy: 50 Gy at 2 Gy/Fx/d on weeks 1-5,followed by 36 Gy in 30 fractions of 1.2 Gy, twice per day,on weeks 6-8 to a total dose of 86 Gy.~concurrent chemotherapy: weekly carboplatin area under the curve (AUC) 1.5-2 and paclitaxel 45-50 mg/m2 over the duration (8 weeks) of radiation therapy.~Adjuvant chemotherapy after high dose chemoradiation is optional.
Study NCT01027143 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 polyunsaturated fatty acids
Description: ProEPA Xtra 1000mg softgels: 3 softgels twice daily
Study NCT01027143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 Fatty Acid
Description: Soybean oil: 3(age 12-25) matched softgel caps twice daily
Study NCT00454909 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine 134612
Description: Single dose intramuscular injection.
Study NCT00454909 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menactra®
Description: Single dose intramuscular injection.
Study NCT01475396 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Study NCT00968552 — intervention group
Intervention type: PROCEDURE
Intervention: Self-expandable stent placement via endoscopy
Description: Self-expandable stent placement via endoscopy
Study NCT04181190 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Total IgE
Description: Levels of total IgE before biological treatments and at 4±2 months of treatments
Study NCT04293744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colloid priming solution for ECC circuit
Description: Prospective, multi-center, double-blinded, randomized, controlled clinical trial
Study NCT04293744 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard priming solution for ECC circuit
Description: Prospective, multi-center, double-blinded, randomized, controlled clinical trial
Study NCT01605630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based family cancer literacy intervention
Description: family based counseling and materials provided in navajo/english including digital stories
Study NCT01605630 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: standard of care
Study NCT03060551 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SVF injection
Description: SVF is increasingly recognised as an easily accessible source of regenerative cells with therapeutic potential in ischaemic or autoimmune disease. We aimed to measure for the first time the safety, tolerability and potential efficacy of autologous SVF cells local injections in patients with systemic sclerosis
Study NCT00888199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental prosthetic foot (K3 Promoter)
Description: Experimental prosthetic foot
Study NCT02929498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2879552
Description: GSK2879552 will be administered orally as continuous daily dosing.
Study NCT02929498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered at 75 mg/m2 from Day 1 to Day 7 of each 28 day cycle by intravenous (iv) infusion or subcutaneous (sc) injection.
Study NCT01642615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole capsules
Study NCT01642615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dexlansoprazole placebo-matching capsules
Study NCT02234518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High quantity fiber
Description: The intervention type is food product
Study NCT02234518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low quantity fiber
Description: The intervention type is food product
Study NCT02234518 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02786823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: tab. Folic acid 5 mg
Study NCT02786823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: tab. Vitamin B12 500 mcg
Study NCT02786823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral hypoglycemic agents [Metformin +/- Sulfonylurea]
Description: Patients receiving either of the following oral hypoglycemic agents~1. Sulfonylurea~2. Metformin~3. Metformin plus Sulfonylurea
Study NCT02786823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral hypoglycemic agents [Metformin +/- Sulfonylurea]
Description: Patients receiving either of the following oral hypoglycemic agents~1. Sulfonylurea~2. Metformin~3. Metformin plus Sulfonylurea
Study NCT04451707 — intervention group
Intervention type: OTHER
Intervention: non-cholera Vibrio infection
Description: Epidemiology of patients diagnosed with non-cholera Vibrio infection
Study NCT00814242 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical resection
Description: radical resection performed in patinets with HCC.
Study NCT00814242 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous radiationfrequency ablation
Description: CT or Ultrasound-guided percutaneous radiofrequency ablation performed in patinets with HCC
Study NCT01370967 — intervention group
Intervention type: OTHER
Intervention: Study formula feeding
Description: Infants who are exclusively fed the new study formula at time of enrollment
Study NCT01370967 — intervention group
Intervention type: OTHER
Intervention: Human milk feeding
Description: Infants who are exclusively fed human milk at time of enrollment
Study NCT01370967 — intervention group
Intervention type: OTHER
Intervention: Mixed feeding
Description: Infants who are exclusively fed human milk and the new study formula at time of enrollment
Study NCT00288574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Study NCT00288574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02078219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170
Description: Oral Treatment
Study NCT02078219 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Allopurinol
Description: Oral Treatment
Study NCT02078219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Treatment
Study NCT03036527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Activity-based locomotor training
Description: The weight-bearing activity-based intervention will be provided via a standardized locomotor training program that is provided clinically at Frazier Rehab Institute within the NeuroRecovery Network (NRN); or similar interventions in a research protocol of stepping (IRB 07.0066).
Study NCT03036527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Activity-based stand training
Description: The weight-bearing activity-based intervention will be provided via a standardized locomotor training program that is provided clinically at Frazier Rehab Institute within the NeuroRecovery Network (NRN); or similar interventions in a research protocol of stand only program (07.0268). The stand only intervention may also be provided as part of this study.
Study NCT03036527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Activity-based upper arm ergometry
Description: The non-weight bearing activity-based upper arm ergometry intervention will be provided via a standardized arm crank therapy provided within this study.
Study NCT03036527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Activity-based training + spinal epidural stimulation
Description: combination effect of both locomotor training and/or stand training with epidural stimulation targeting locomotion and/or stand.
Study NCT01526421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: monetary reinforcer
Description: Participants randomized to the reinforcer arm will receive gift cards at the completion of screening procedures.
Study NCT01891071 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung volume recruitment
Description: Inflation of the lungs to their maximal insufflation capacity by the consecutive delivery, by a manual resuscitator in this study, of volumes of air that are held with a closed glottis
Study NCT02796105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progevera
Study NCT02796105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orgalutran
Study NCT03341676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 3.3 mg/mL solution for injection
Study NCT03341676 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride 0.9% w/v solution for injection
Study NCT00046228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abciximab placebo; reteplase placebo, abciximab, abciximab
Description: placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
Study NCT00046228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab; reteplase; abciximab placebo; abciximab
Description: 0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
Study NCT00046228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abciximab; reteplase placebo; abciximab placebo; abciximab
Description: 0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
Study NCT00046228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abciximab placebo; reteplase placebo, abciximab, abciximab
Description: placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
Study NCT00046228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abciximab; reteplase placebo; abciximab placebo; abciximab
Description: 0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
Study NCT00046228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab; reteplase; abciximab placebo; abciximab
Description: 0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
Study NCT01967290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibratory feedback and 3D movement analysis
Description: Hand-to-mouth task performed under vibratory feedback combined with 3D continuous movement analysis.
Study NCT01967290 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Only 3D movement analysis
Description: Hand-to-mouth task performed under 3D continuous movement analysis only
Study NCT02254343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: proximal robot-assisted therapy
Study NCT02254343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: distal robot-assisted therapy
Study NCT02254343 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: individualized intensive therapy
Study NCT04181190 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood cell counts
Description: White Blood Cell Count and Differential (and in particular the levels of total leucocytes, lymphocytes, eosinophils and basophils)
Study NCT05222074 — intervention group
Intervention type: OTHER
Intervention: Venous congestion
Description: Venous congestion exposures were quantified as area under the curve (AUC) of central venous pressure ≥12, 16 or 20 mmHg
Study NCT05222074 — intervention group
Intervention type: OTHER
Intervention: Introperation hypotension
Description: Introperation hypotension exposures were quantified as area under the curve (AUC) of mean arterial pressure ≤55, 65, 75 mmHg
Study NCT04181190 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Asthma control assessment
Description: Levels of asthma control assessed by asthma control questionnaire (ACT) before initiation of biological treatments and at 4± months of treatments
Study NCT04181190 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: lung function tests
Description: Lung function tests performed before initiation of biological treatments and at 4± months of treatments
Study NCT04175379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group 40
Description: During surgery, the TV(tidal volume) should maintain 6ml/kg (ideal body weight). After position change and OLV(one lung ventilation) for operation, each patient adjusts RR(respiratory rate) to reach target PaCO2 40 ± 5mmHg. Hemodynamic records and arterial blood tests are performed at the following times: After tracheal intubation, 15 minutes after in two lung ventilatory state at the supine position (T0), after 30 minutes reaching to the target PaCO2 by adjusting RR at the lateral position starting one lung ventilation (T1), and after 60 minutes while maintaining target PaCO2 (T2).
Study NCT04175379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group 50
Description: During surgery, the TV(tidal volume) should maintain 6ml/kg (ideal body weight). After position change and OLV(one lung ventilation) for operation, each patient adjusts RR(respiratory rate) to reach target PaCO2 50 ± 5mmHg. Hemodynamic records and arterial blood tests are performed at the following times: After tracheal intubation, 15 minutes after in two lung ventilatory state at the supine position (T0), after 30 minutes reaching to the target PaCO2 by adjusting RR at the lateral position starting one lung ventilation (T1), and after 60 minutes while maintaining target PaCO2 (T2).
Study NCT02113397 — intervention group
Intervention type: DRUG
Intervention: TOBI™ Podhaler™ 112 mg inhaled twice daily
Study NCT04175379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group 60
Description: During surgery, the TV(tidal volume) should maintain 6ml/kg (ideal body weight). After position change and OLV(one lung ventilation) for operation, each patient adjusts RR(respiratory rate) to reach target PaCO2 60 ± 5mmHg. Hemodynamic records and arterial blood tests are performed at the following times: After tracheal intubation, 15 minutes after in two lung ventilatory state at the supine position (T0), after 30 minutes reaching to the target PaCO2 by adjusting RR at the lateral position starting one lung ventilation (T1), and after 60 minutes while maintaining target PaCO2 (T2).
Study NCT01085045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT003 MDI
Description: Inhaled PT003 MDI administered as two puffs BID for 7 days
Study NCT01085045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT005 MDI
Description: Inhaled PT005 MDI administered as two puffs BID for 7 days
Study NCT01085045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI
Description: Inhaled placebo administered as two puffs BID for 7 days
Study NCT01085045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium bromide 18 μg (Spiriva Handihaler®)
Description: Inhaled tiotropium bromide 18 μg (Spiriva Handihaler®) administered QD for 7 days
Study NCT01085045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Fumarate 12 μg (Foradil® Aerolizer®)
Description: Inhaled formoterol fumarate 12 μg (Foradil® Aerolizer®) administered BID for 7 days
Study NCT01085045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT001 MDI
Description: Inhaled PT001 MDI administered as two puffs BID for 7 days
Study NCT04164745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib, oral capsule
Description: Participants receive Anlotinib 12 mg p.o, qd on Days 1-14 of each 3-week cycle until progressive disease or unacceptable toxicity plus pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
Study NCT04164745 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants receive Anlotinib 12 mg p.o, qd on Days 1-14 of each 3-week cycle until progressive disease or unacceptable toxicity plus pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
Study NCT06181006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered orally.
Study NCT01954264 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Capillary blood sample
Description: Capillary blood sample (up to 200µL) for determination of PP (blood slides).
Study NCT01954264 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Data collection
Description: Prospective data collection at the study visit by the internet based Electronic Case Report Form (eCRF)
Study NCT02804204 — intervention group
Intervention type: DRUG
Intervention: Anti-TNF
Study NCT00403039 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ranibizumab (Lucentis )
Study NCT03637153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment at Low Altitude (470m above sea level)
Description: Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
Study NCT03637153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to High Altitude (2500m above sea level)
Description: Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
Study NCT01013025 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound or CT or MRI to locate implant
Description: Scanning methods (eg, ultrasound, CT, or MRI) were used to locate the implant.
Study NCT02709278 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: BCG
Description: BCG SSI (Due to a global shortage of BCG SSI, BCG Bulgaria used in Group 2)
Study NCT02709278 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: BCG SSI (Due to a global shortage of BCG SSI, BCG Bulgaria used in Group 2)
Study NCT02709278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Saline placebo
Study NCT02709278 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: BCG
Description: BCG Bulgaria (InterVax)
Study NCT02709278 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: BCG Bulgaria (InterVax)